A prospective phase II study of neoadjuvant chemoradiotherapy (CRT) for resectable esophageal squamous cell carcinoma was conducted from May 1993 to March 1996.
Missing: sca_esv= ea3495c7dcf845bc
Oct 6, 2020 · Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 8 Department of Clinical Haematology, Barwon Health, ...
Missing: sca_esv= ea3495c7dcf845bc
Mar 1, 2018 · Recessive mutations in the mitochondrial copper-binding protein SCO2, cytochrome c oxidase (COX) assembly protein, have been reported in ...
Missing: sca_esv= ea3495c7dcf845bc
Arterial ischemia and hemorrhage are associated with bevacizumab, an inhibitor of vascular endothelial growth factor that is widely used to treat many types ...
Missing: sca_esv= ea3495c7dcf845bc
Treatment with atorvastatin to the National Cholesterol Educational ...
pubmed.ncbi.nlm.nih.gov › ...
Background: Atorvastatin is very effective in reducing plasma low-density lipoprotein cholesterol (LDL-C) levels. However, there is no long-term survival study ...
Missing: sca_esv= ea3495c7dcf845bc
This tool uses predefined filters to help you quickly refine PubMed searches on clinical or disease-specific topics. To use this tool, enter your search terms ...
Missing: sca_esv= ea3495c7dcf845bc
The study regimen consisting of 2 cycles of neoadjuvant therapy was completed without a clinically significant QOL deterioration. A transient increase in ...
Missing: sca_esv= ea3495c7dcf845bc
Background: Intraductal US can improve the diagnostic accuracy of cholangiography performed under C-arm fluoroscopy in patients with suspected ...
Missing: sca_esv= ea3495c7dcf845bc
People also ask
How to search PubMed for clinical trials?
PubMed Clinical Queries
The Clinical Queries link is found on the PubMed home page or under the More Resources drop-down at the top of the Advanced Search page. Enter your search terms, and evidence-filtered citations will appear under Clinical Study Categories, Systematic Reviews, or Medical Genetics.
What are the results of the Tazemetostat clinical trial?
Steven Park, MD: This study published in Lancet Oncology in 2020 was a large phase 2 study of tazemetostat as a single agent in relapsed or refractory follicular lymphoma. In this study, tazemetostat showed an overall response rate of 69%, with a complete response rate of 13% in EZH2-mutated follicular lymphoma.
In order to show you the most relevant results, we have omitted some entries very similar to the 8 already displayed.
If you like, you can repeat the search with the omitted results included. |